Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-14T22:14:06.484Z Has data issue: false hasContentIssue false
  • English
  • Français

Current and Emerging Treatments for Cervical Dystonia

Published online by Cambridge University Press:  07 November 2014

Stewart A. Factor ,
Mark F. Lew  and
Richard M. Trosch
Get access Rights & Permissions [Opens in a new window]

Abstract

Cervical dystonia (CD), also known as spasmodic torticollis, is the most common of the focal dystonias. Muscle hypertrophy is present in nearly all patients, and neck pain is associated with CD in about 80% of patients. Remissions can occur in about 20% of patients, though most last under a year.

Medical therapies have not generally worked well for patients with CD, and are typically associated with many side effects. Botulinum toxin (BT), which causes fewer side effects, has been considered the treatment of choice. Beyond medical therapy, various surgeries for CD have been performed for many decades. Of surgical treatments now in use, selective peripheral denervation is the most common.

In CD, botulinum toxin type A (BT-A) targets pain, dystonic posturing, limited range of motion, and tremor. BT type B (BT-B) is a serotype of BT that is ontogenetically distinct from the type A toxin. There have been three randomized, multicenter, double-blind, placebo-controlled trials of BT-B. It appears that BT-B is a safe and effective treatment for patients with CD who are responsive or resistant to BT-A.

Type
Research Article
Information
CNS Spectrums , Volume 5 , supplement S5: Current and Emerging Treatments for Cervical Dystonia , June 2000 , pp. s1 - s8
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Greene, PE, Bressman, S. Exteroceptive and interoceptive stimuli in dystonia. Mov Disord. 1998;13:549–551.CrossRefGoogle ScholarPubMed
2.Krauss, JK, Toups, EG, Jankovic, J, Grossman, RG. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997;63:642–648.CrossRefGoogle ScholarPubMed
3.Lew, MF, Adornato, BT, Duane, DD, et al.Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49:701–707.CrossRefGoogle ScholarPubMed
4.Brashear, A, Lew, MF, Dykstra, DD, et al.Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53:1439–1446.CrossRefGoogle ScholarPubMed
5.Brin, MF, Lew, MF, Adler, CH, et al.Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53:1431–1438.CrossRefGoogle ScholarPubMed